Understanding The Biology and Potential of LARP1 (G23367)

Target Name: LARP1

NCBI ID: G23367

LARP1

Understanding The Biology and Potential of LARP1

LARP1 (LARP-1), also known as interleukin-18 (IL-18), is a protein that is expressed in various tissues throughout the body, including immune cells, epithelial cells, and muscles. It is a key regulator of inflammation and immune responses, and has been implicated in a number of diseases, including cancer, autoimmune disorders, and chronic obstructive pulmonary disease (COPD).

In recent years, researchers have been interested in using LARP1 as a drug target or biomarker because of its unique biology and the potential it holds for treating a variety of diseases. One of the main reasons for this interest is the fact that LARP1 is a pro-inflammatory protein, which means that it promotes inflammation in response to various stimuli. However, unlike many other pro-inflammatory proteins, LARP1 has been shown to have both pro-inflammatory and anti-inflammatory effects, which can make it an attractive target for drugs that want to either activate or inhibit inflammation.

One of the key challenges in studying LARP1 is its complex biology, as it is expressed in a wide range of tissues and cells, and can interact with many different proteins and factors. This makes it difficult to understand exactly how LARP1 works and how it might be affected by different treatments. However, researchers have made some progress in understanding the basic mechanisms that LARP1 is involved in, and are using this knowledge to develop new treatments.

One of the key ways that LARP1 is being studied is through its effects on inflammation. LARP1 has been shown to promote the production of pro-inflammatory cytokines, such as TNF-alpha, IL-1, and IL-6, in response to various stimuli, such as bacteria, viruses, or cancer cells. It has also been shown to contribute to the recruitment of immune cells to the site of inflammation, which can help to exacerbate the inflammatory response.

In addition to its role in inflammation, LARP1 has also been shown to have anti-inflammatory effects. For example, studies have shown that LARP1 can inhibit the production of pro-inflammatory cytokines in a variety of cells, such as macrophages and dendritic cells. This makes it possible that LARP1 could be a useful target for drugs that want to reduce inflammation and prevent the development of various diseases.

Another potential application of LARP1 as a drug target is its role in cancer. LARP1 has been shown to be expressed in various types of cancer, including breast cancer, lung cancer, and colon cancer. It has also been shown to contribute to the development and progression of these cancers by promoting the growth and survival of cancer cells. As a result, LARP1 has become an attractive target for drugs that want to inhibit its role in cancer development and progression.

In addition to its potential as a cancer target, LARP1 has also been shown to be involved in a number of other biological processes that are important for human health. For example, it has been shown to play a role in the regulation of pain and inflammation, and has been implicated in a variety of other diseases, including autoimmune disorders and respiratory diseases.

Given the complexity and importance of LARP1, it is no wonder that researchers are actively working to develop new treatments that target this protein. There are currently a variety of different LARP1-based therapies being developed for various diseases, including cancer, autoimmune disorders, and COPD. These therapies are designed to either inhibit the pro-inflammatory effects of LARP1 or to boost its anti-inflammatory effects, depending on the

Protein Name: La Ribonucleoprotein 1, Translational Regulator

Functions: RNA-binding protein that regulates the translation of specific target mRNA species downstream of the mTORC1 complex, in function of growth signals and nutrient availability (PubMed:20430826, PubMed:23711370, PubMed:24532714, PubMed:25940091, PubMed:28650797, PubMed:28673543, PubMed:29244122). Interacts on the one hand with the 3' poly-A tails that are present in all mRNA molecules, and on the other hand with the 7-methylguanosine cap structure of mRNAs containing a 5' terminal oligopyrimidine (5'TOP) motif, which is present in mRNAs encoding ribosomal proteins and several components of the translation machinery (PubMed:23711370, PubMed:25940091, PubMed:28650797, PubMed:29244122, PubMed:26206669, PubMed:28379136). The interaction with the 5' end of mRNAs containing a 5'TOP motif leads to translational repression by preventing the binding of EIF4G1 (PubMed:25940091, PubMed:28650797, PubMed:29244122, PubMed:28379136). When mTORC1 is activated, LARP1 is phosphorylated and dissociates from the 5' untranslated region (UTR) of mRNA (PubMed:25940091, PubMed:28650797). Does not prevent binding of EIF4G1 to mRNAs that lack a 5'TOP motif (PubMed:28379136). Interacts with the free 40S ribosome subunit and with ribosomes, both monosomes and polysomes (PubMed:20430826, PubMed:24532714, PubMed:25940091, PubMed:28673543). Under normal nutrient availability, interacts primarily with the 3' untranslated region (UTR) of mRNAs encoding ribosomal proteins and increases protein synthesis (PubMed:23711370, PubMed:28650797). Associates with actively translating ribosomes and stimulates translation of mRNAs containing a 5'TOP motif, thereby regulating protein synthesis, and as a consequence, cell growth and proliferation (PubMed:20430826, PubMed:24532714). Stabilizes mRNAs species with a 5'TOP motif, which is required to prevent apoptosis (PubMed:20430826, PubMed:23711370, PubMed:25940091, PubMed:28673543)

The "LARP1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LARP1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets